Navigation Links
Research leads to better understanding of peripheral neuropathy
Date:3/5/2013

One in 25,000 people worldwide is affected by neurofibromatosis type 2 (NF2), a condition where the loss of a tumour suppressor called Merlin results in multiple tumours in the brain and nervous system.

Sufferers may experience 20 to 30 tumours at any one time and such numbers often lead to hearing loss, disability and eventually death. Those with NF2 may also experience peripheral neuropathy, which is when the nerves carrying messages to and from the brain and spinal column to the rest of the body do not work.

Peripheral neuropathy leads to further complications for NF2 sufferers, such as pain and numbness, muscle problems, problems with body organs and other symptoms of nerve damage, such as bladder problems, uncontrollable sweating and sexual dysfunction.

Researchers from Plymouth University Peninsula Schools of Medicine and Dentistry are part of an international research team which has for the first time identified the role of a tumour suppressor called Merlin in regulating the integrity of axons. Axons are nerve fibres which transmit information around the body and it is these are that damaged in peripheral neuropathy.

The research team showed that Merlin regulates a protein called neurofilament which supplies structural support for the axon.

A better understanding of this mechanism could lead to effective drug therapies to alleviate the symptoms of peripheral neuropathy in patients with NF2.

The results of the research is published this week in Nature Neuroscience.


'/>"/>

Contact: Andrew Gould
andrew.gould@pcmd.ac.uk
44-188-438-346
University of Plymouth
Source:Eurekalert

Page: 1

Related medicine news :

1. U of M researchers find wide variation in cesarean delivery rates among US hospitals
2. New Center for Open Science designed to increase research transparency
3. BUSM researchers use goal-oriented therapy to treat diabetic neuropathies
4. Researchers Describe 1st Functional Cure of HIV in Baby
5. Research Finds Use of Volpara Objective Breast Density Software from Matakina Helps Overcome the Limitations of Mammography for Women with Dense Breasts
6. Pediatric cancer charities partner to fund international collaborative research
7. Industry and academic researchers gather for innovative accelerating cancer cures research symposium
8. Researchers describe first functional HIV cure in an infant
9. Researchers discover how to shutdown cancers powerful master protein
10. Research and Markets - Drug Delivery in Cancer - Technologies, Markets and Companies - 2013 Report
11. Research: Brain cant cope with making a left-hand turn and talking on hands-free cell phone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... ... February 17, 2017 , ... ... disruptive innovation in the industry, according to the recent NEJM Catalyst Insights Report ... surveys of the NEJM Catalyst Insights Council, a qualified group of U.S. executives, ...
(Date:2/18/2017)... ... 18, 2017 , ... A new directory from the Senior ... easily connect elderly veterans of America's armed forces to a range of senior ... material on this year's increase in the Veterans Pension with Aid & Attendance ...
(Date:2/17/2017)... TN (PRWEB) , ... February 17, 2017 , ... ... Inc. (ISTS) brings its educational assistance management solution to the exhibit floor for ... Center in Orlando, Fla. , From Feb. 19–23, 2017, more than 40,000 ...
(Date:2/17/2017)... ... February 17, 2017 , ... Access today ... Exhibition in Orlando, Fla., February 19-23. Visitors to the company’s booth (#1778) will ... used electronic patient signatures solution in healthcare . , Since it first ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... exhibitor at Molecular Medicine Tri-Conference February 20 – 22 in San Francisco. As ... showcase its anatomic and molecular pathology workflow solution, as well as its new ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... -- Noble Capital Markets announced today that it has initiated ... EPIX ). The report was issued by Noble,s Head ... ESSA Pharmaceuticals is a clinical stage biopharmaceutical company ... lead compound EPI-506, is a small molecule oral drug ... receptor, thereby has potential to overcome some of the ...
(Date:2/16/2017)... , Feb. 16, 2017 Quest Diagnostics ... of diagnostic information services, today announced that it has ... for 2017 by Fortune. The annual ... companies in the "Health Care: Pharmacy and Other Services" ... diagnostic information services company to attain the designation. This ...
(Date:2/16/2017)... , Feb. 16, 2017  Aralez Pharmaceuticals Inc. (NASDAQ: ... pharmaceutical company, today announced that executive management will participate ... be held February 22-23, 2017. Adrian Adams , ... Company at 1:35 p.m. local time on Wednesday, February ... archive for the event may be accessed from the ...
Breaking Medicine Technology: